A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > BUSINESS
BUSINESS
- General Logistics Companies Increasing Their Investment in Field of Drug Distribution; Opening More Specialized Warehouses
September 6, 2013
- Edoxaban Shows Non-Inferiority to Warfarin for VTE: Daiichi Sankyo
September 6, 2013
- Will Once-weekly Formulations and New Products Help GLP-1 Receptor Agonists Break Out of Their Slump?
September 6, 2013
- Teva Japan to Pursue High-Value-Added Generics, Eyes Partnerships with Japanese Companies: Chairman Krinsky
September 5, 2013
- Teva Pharma Japan Aims for the Top in Japan Generic Market by 2018: President
September 5, 2013
- Kyowa Kirin Ties Up with Ultragenyx for XLH Treatment KRN23
September 5, 2013
- ASKA to Launch Generic Biz Unit; Takeda’s Yonezawa to Take Helm
September 4, 2013
- Otsuka Paid 20 Billion Yen to Healthcare Professionals in FY2012, 5.4 Billion Yen for Information Provisioning
September 4, 2013
- Fuji Yakuhin, Sanwa Kagaku Launch Gout and Hyperuricemia Treatments Topiloric/Uriadec
September 4, 2013
- President or Head of General Medicine OK’ed Research Grants to 2 Universities: Novartis Exec
September 3, 2013
- Astellas, MSD to Tie Up for SGLT-2 Inhibitor Ipragliflozin
September 3, 2013
- Chugai, Taisho Toyama to Offer Compliance Advantages with Once-Monthly Bonviva
September 3, 2013
- MTPC’s SGLT-2 Inhibitor Canagliflozin Now No. 1 in Prescription Share in US, Overtaking Januvia
September 3, 2013
- Astellas Paid 19.3 Billion Yen to Healthcare Professionals, 7.1 Billion Yen for Information Provisioning in FY2012
September 3, 2013
- Takeda’s OBLEAN Near-Certain to Debut as Japan’s 1st Anti-Obesity Drug in 20 Years
September 2, 2013
- Daiichi Sankyo Provided 36.6 Billion Yen to Physicians, Medical Institutions in FY2012, 22.7 Billion Yen for R&D
September 2, 2013
- US FDA Requests Additional Data for Tolvaptan for Treatment of ADPKD: Otsuka
September 2, 2013
- Orphan Drug Wholesaler S.D. Next to Swing into Black in FY2015 with Tailored Distribution Services: Pres.
August 30, 2013
- WHO Grants Prequalification to Eisai for Lymphatic Filariasis Treatment
August 30, 2013
- New Products Shake Up Market for Osteoporosis Treatments; Entry of Pralia Could Lead to Change in Market Structure
August 30, 2013
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…